-
公开(公告)号:US08889137B2
公开(公告)日:2014-11-18
申请号:US13499429
申请日:2010-10-01
申请人: Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer , Edelgard Schneweis
发明人: Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer
IPC分类号: A61K39/245 , C07K16/08 , A61K39/00
CPC分类号: C07K16/087 , A61K39/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.
摘要翻译: 本发明涉及权利要求中定义的抗HSV抗体,包含有效量的所述抗体的药物组合物,包含编码所述抗体的核苷酸序列的表达载体,包含所述核苷酸的宿主细胞 序列,能够产生所述抗体的杂交瘤细胞和所述抗体作为药物的用途,特别是用于制备用于预防或治疗性治疗受试者中HSV相关疾病的药物; 如权利要求中所限定。
-
公开(公告)号:US20130058952A1
公开(公告)日:2013-03-07
申请号:US13499429
申请日:2010-10-01
申请人: Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Edelgard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer
发明人: Michael Roggendorf , Anna-Maria Eis-Hübinger , Jürgen Krauss , Karl Eduard Schneweis , Edelgard Schneweis , Michaela Arndt , Adalbert Krawczyk , Evelyn Exner , Martin P. Däumer
CPC分类号: C07K16/087 , A61K39/00 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.
-